NYSE:ABT - Abbott Laboratories Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$70.41 -0.35 (-0.49 %)
(As of 12/17/2018 11:44 AM ET)
Previous Close$70.76
Today's Range$69.17 - $70.62
52-Week Range$54.84 - $74.92
Volume212,629 shs
Average Volume6.21 million shs
Market Capitalization$124.28 billion
P/E Ratio28.22
Dividend Yield1.58%
Beta1.4
Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. It operates through the following segments: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, Cardiovascular and Neuromodulation Products, and Other. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Vascular Products segment trades coronary, endovascular, structural heart, vessel closure, and other medical device products. The Other segment comprises of Abbott Medical Optics. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Receive ABT News and Ratings via Email

Sign-up to receive the latest news and ratings for ABT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNYSE:ABT
Previous Symbol
CUSIP00282410
Phone224-667-6100

Debt

Debt-to-Equity Ratio0.62
Current Ratio1.42
Quick Ratio1.13

Price-To-Earnings

Trailing P/E Ratio28.22
Forward P/E Ratio24.36
P/E Growth2.1

Sales & Book Value

Annual Sales$27.39 billion
Price / Sales4.51
Cash Flow$4.7639 per share
Price / Cash Flow14.78
Book Value$17.87 per share
Price / Book3.94

Profitability

EPS (Most Recent Fiscal Year)$2.50
Net Income$477 million
Net Margins2.91%
Return on Equity16.05%
Return on Assets6.95%

Miscellaneous

Employees99,000
Outstanding Shares1,756,330,000
Market Cap$124.28 billion
OptionableOptionable

Abbott Laboratories (NYSE:ABT) Frequently Asked Questions

What is Abbott Laboratories' stock symbol?

Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."

How often does Abbott Laboratories pay dividends? What is the dividend yield for Abbott Laboratories?

Abbott Laboratories announced a quarterly dividend on Friday, December 14th. Stockholders of record on Tuesday, January 15th will be given a dividend of $0.32 per share on Friday, February 15th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 1.84%. This is a boost from Abbott Laboratories's previous quarterly dividend of $0.28. View Abbott Laboratories' Dividend History.

How were Abbott Laboratories' earnings last quarter?

Abbott Laboratories (NYSE:ABT) issued its earnings results on Wednesday, October, 17th. The healthcare product maker reported $0.75 earnings per share for the quarter, hitting the consensus estimate of $0.75. The healthcare product maker had revenue of $7.66 billion for the quarter, compared to analyst estimates of $7.65 billion. Abbott Laboratories had a return on equity of 16.05% and a net margin of 2.91%. The company's quarterly revenue was up 12.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.66 EPS. View Abbott Laboratories' Earnings History.

When is Abbott Laboratories' next earnings date?

Abbott Laboratories is scheduled to release their next quarterly earnings announcement on Wednesday, January 23rd 2019. View Earnings Estimates for Abbott Laboratories.

What guidance has Abbott Laboratories issued on next quarter's earnings?

Abbott Laboratories updated its FY18 earnings guidance on Wednesday, October, 17th. The company provided earnings per share (EPS) guidance of $2.87-2.89 for the period, compared to the Thomson Reuters consensus estimate of $2.88. Abbott Laboratories also updated its FY 2018 guidance to $2.87-2.89 EPS.

What price target have analysts set for ABT?

20 brokerages have issued 1-year price objectives for Abbott Laboratories' shares. Their forecasts range from $64.00 to $86.00. On average, they anticipate Abbott Laboratories' share price to reach $75.5842 in the next twelve months. This suggests a possible upside of 8.7% from the stock's current price. View Analyst Price Targets for Abbott Laboratories.

What is the consensus analysts' recommendation for Abbott Laboratories?

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abbott Laboratories in the last year. There are currently 4 hold ratings and 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Abbott Laboratories.

Has Abbott Laboratories been receiving favorable news coverage?

News headlines about ABT stock have trended somewhat positive on Monday, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Abbott Laboratories earned a coverage optimism score of 1.0 on InfoTrie's scale. They also gave news coverage about the healthcare product maker a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

Who are some of Abbott Laboratories' key competitors?

Who are Abbott Laboratories' key executives?

Abbott Laboratories' management team includes the folowing people:
  • Miles D. White, Chairman & Chief Executive Officer
  • Robert B. Ford, President & Chief Operating Officer
  • Brian Bernard Yoor, Chief Financial Officer & Executive VP-Finance
  • James E. Young, Chief Compliance & Ethics Officer, Vice President
  • Hubert L. Allen, Secretary, Executive VP & General Counsel

Who are Abbott Laboratories' major shareholders?

Abbott Laboratories' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (7.91%), Vanguard Group Inc (7.91%), Capital Research Global Investors (7.13%), BlackRock Inc. (6.67%), Massachusetts Financial Services Co. MA (2.20%) and Bank of New York Mellon Corp (1.55%). Company insiders that own Abbott Laboratories stock include Alejandro D Wellisch, Andrew H Lane, Brian J Blaser, Daniel Gesua Sive Salvadori, Daniel J Starks, Deepak S Nath, Heather L Mason, Hubert L Allen, Jaime Contreras, Jared Watkin, Joseph J Manning, Michael J Pederson, Michael J Warmuth, Miles D White, Robert E Funck, Roger Bird, Sharon J Bracken and Stephen R Fussell. View Institutional Ownership Trends for Abbott Laboratories.

Which institutional investors are selling Abbott Laboratories stock?

ABT stock was sold by a variety of institutional investors in the last quarter, including Capital Research Global Investors, Mitsubishi UFJ Trust & Banking Corp, TIAA CREF Investment Management LLC, Marshall Wace North America L.P., Diamond Hill Capital Management Inc., Alliancebernstein L.P., Canada Pension Plan Investment Board and Bahl & Gaynor Inc.. Company insiders that have sold Abbott Laboratories company stock in the last year include Andrew H Lane, Brian J Blaser, Daniel Gesua Sive Salvadori, Jaime Contreras, Jared Watkin, Michael J Pederson, Miles D White, Roger Bird, Sharon J Bracken and Stephen R Fussell. View Insider Buying and Selling for Abbott Laboratories.

Which institutional investors are buying Abbott Laboratories stock?

ABT stock was bought by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Capital International Investors, Matthew Goff Investment Advisor LLC, Vanguard Group Inc, Vanguard Group Inc., Capital World Investors, Federated Investors Inc. PA and Sustainable Growth Advisers LP. Company insiders that have bought Abbott Laboratories stock in the last two years include Brian J Blaser and Daniel J Starks. View Insider Buying and Selling for Abbott Laboratories.

How do I buy shares of Abbott Laboratories?

Shares of ABT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Abbott Laboratories' stock price today?

One share of ABT stock can currently be purchased for approximately $69.5450.

How big of a company is Abbott Laboratories?

Abbott Laboratories has a market capitalization of $124.28 billion and generates $27.39 billion in revenue each year. The healthcare product maker earns $477 million in net income (profit) each year or $2.50 on an earnings per share basis. Abbott Laboratories employs 99,000 workers across the globe.

What is Abbott Laboratories' official website?

The official website for Abbott Laboratories is http://www.abbott.com.

How can I contact Abbott Laboratories?

Abbott Laboratories' mailing address is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. The healthcare product maker can be reached via phone at 224-667-6100.


MarketBeat Community Rating for Abbott Laboratories (NYSE ABT)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  710 (Vote Outperform)
Underperform Votes:  571 (Vote Underperform)
Total Votes:  1,281
MarketBeat's community ratings are surveys of what our community members think about Abbott Laboratories and other stocks. Vote "Outperform" if you believe ABT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/17/2018 by MarketBeat.com Staff

Featured Article: Return on Investment (ROI)

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel